Hana’a Hezam Algadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hana’a Hezam Algadi has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Omer Mohammed Jamali
Department of Dentistry, Faculty of Medicine and Health Sciences, University of Science and Technology, Aden, Yemen
2 shared publications - Ahmed A. Abd-Rabou
Hormones Department, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt
1 shared publication - Ahmed Yaseen Alqutaibi
Department of Prosthodontics, Faculty of Dentistry, Ibb University, Ibb, Yemen
1 shared publication Amany Abd-Elhameed Abou-Bakr
Department of Pathology, National Cancer Institute, Cairo University, Cairo, Egypt
1 shared publicationBushra Hussein
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Ibn Al-Nafis University for medical sciences, Sana’a, Yemen
1 shared publicationFerdus Zahrah
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Ibn Al-Nafis University for medical sciences, Sana’a, Yemen
1 shared publication
Latest Publications
- Open Access
- 18 July 2026
- Published by Springer Nature in BDJ Open
- Vol. 12 (1) , 75
Are dental practitioners prepared to recognize stomatognathic movement disorders? A cross-sectional study of knowledge, diagnostic confidence, and educational needs
Background Stomatognathic movement disorders (SMDs) are uncommon but clinically significant neurological conditions that frequently present with orofacial manifestations. Because affected patients may initially seek care from dental practitioners, limited awareness of these disorders could contribute to diagnostic confusion with temporomandibular disorders (TMDs) and may have implications for timely referral and appropriate patient management. This study evaluated dental practitioners’ knowledge, diagnostic confidence, and educational preparedness regarding SMDs. Methods A cross-sectional survey was conducted among dental practitioners using a validated self-administered online questionnaire. Knowledge scores were calculated out of 25 points and expressed as percentages. Comparative analyses were performed across educational levels using one-way ANOVA, chi-square tests, and multivariable logistic regression. Results A total of 156 dental practitioners participated. Mean knowledge scores differed significantly across academic level (Bachelor: 44.05%, Master: 48.95%, Doctorate: 63.71%; p < 0.001). Doctoral-level education independently predicted adequate knowledge (OR = 8.54, 95% CI: 2.09–34.97; p = 0.003), whereas master’s-level showed no significant effect. Knowledge gaps were observed in several domains, particularly in distinguishing SMDs from TMDs and in the management of oromandibular dystonia. Only a minority of participants correctly recognized that temporomandibular joint radiographs are not routinely required prior to treatment. Self-reported clinical confidence was generally low, with only 1.1% of general dentists reporting the ability to independently manage suspected SMD cases. Nevertheless, 94.9% of participants supported integrating SMD-related content into dental curricula. Conclusion The surveyed dental practitioners demonstrated important knowledge gaps regarding SMDs. These findings highlight opportunities to strengthen undergraduate and continuing dental education in the recognition, differentiation from TMDs, and appropriate referral of patients with suspected SMDs.
- 18 July 2026
- Published by Springer Nature in BDJ Open
- Vol. 12 (1) , 75
Open AccessAre dental practitioners prepared to recognize stomatognathic movement disorders? A cross-sectional study of knowledge, diagnostic confidence, and educational needs
Background Stomatognathic movement disorders (SMDs) are uncommon but clinically significant neurological conditions that frequently present with orofacial manifestations. Because affected patients may initially seek care from dental practitioners, limited awareness of these disorders could contribute to diagnostic confusion with temporomandibular disorders (TMDs) and may have implications for timely referral and appropriate patient management. This study evaluated dental practitioners’ knowledge, diagnostic confidence, and educational preparedness regarding SMDs. Methods A cross-sectional survey was conducted among dental practitioners using a validated self-administered online questionnaire. Knowledge scores were calculated out of 25 points and expressed as percentages. Comparative analyses were performed across educational levels using one-way ANOVA, chi-square tests, and multivariable logistic regression. Results A total of 156 dental practitioners participated. Mean knowledge scores differed significantly across academic level (Bachelor: 44.05%, Master: 48.95%, Doctorate: 63.71%; p < 0.001). Doctoral-level education independently predicted adequate knowledge (OR = 8.54, 95% CI: 2.09–34.97; p = 0.003), whereas master’s-level showed no significant effect. Knowledge gaps were observed in several domains, particularly in distinguishing SMDs from TMDs and in the management of oromandibular dystonia. Only a minority of participants correctly recognized that temporomandibular joint radiographs are not routinely required prior to treatment. Self-reported clinical confidence was generally low, with only 1.1% of general dentists reporting the ability to independently manage suspected SMD cases. Nevertheless, 94.9% of participants supported integrating SMD-related content into dental curricula. Conclusion The surveyed dental practitioners demonstrated important knowledge gaps regarding SMDs. These findings highlight opportunities to strengthen undergraduate and continuing dental education in the recognition, differentiation from TMDs, and appropriate referral of patients with suspected SMDs.
- Open Access
- 15 August 2025
- Published by Andover House Inc in Precision Nanomedicine
- Vol. 8 (3) , 1570-1585
Therapeutic efficacy of quercetin versus its encapsulated nanoparticle on tongue squamous cell carcinoma cell line
Quercetin, a bioactive flavonoid, has well-documented antitumour properties; however, its clinical application is limited by its hydrophobicity, poor bioavailability, and stability. These limitations can be addressed via the use of nanotechnology-based drug delivery systems. In this study, we sought to develop polylactide-coglycolide nanoparticles functionalized with polyethylene glycol as the drug vehicle for encapsulating quercetin, and further investigated their anticancer potential against the human tongue squamous cell carcinoma cell line HNO-97 by comparing their effica-cy with that of free quercetin and doxorubicin as standard chemotherapeutic control. Quercetin NPs (QNPs) were synthesized and characterized for particle size, zeta potential, and entrapment efficiency via dynamic light scattering and for morphology via transmission electron microsco-py. The cytotoxicity was evaluated at two time intervals (4 and 24 hours) via the MTT assay. Apoptosis analysis was performed via flow cytometry, and the gene expression levels of Bax, Bcl-2, and PI3K were evaluated via RT-qPCR. After 24 hours of treatment, the in vitro cell cyto-toxicity study revealed that, compared with free quercetin (59.7 µM) and DOX (74.7 µM), QNPs exhibited superior cytotoxicity (IC₅₀ = 41.4 µM). The anticancer efficacy of the QNPs was fur-ther confirmed by enhanced cellular apoptosis. Moreover, treating cells with QNPs resulted in increase in the Bax expression level and the decrease in the Bcl-2 and PI3K expression levels, resulting in the highest Bax/Bcl-2 ratio (31.03). In conclusion, the overall study results suggest that quercetin encapsulated PLGA-PEG nanoparticles may serve as potential drug candidates for the treatment of human tongue squamous cell carcinoma.
- 15 August 2025
- Published by Andover House Inc in Precision Nanomedicine
- Vol. 8 (3) , 1570-1585
Open AccessTherapeutic efficacy of quercetin versus its encapsulated nanoparticle on tongue squamous cell carcinoma cell line
Quercetin, a bioactive flavonoid, has well-documented antitumour properties; however, its clinical application is limited by its hydrophobicity, poor bioavailability, and stability. These limitations can be addressed via the use of nanotechnology-based drug delivery systems. In this study, we sought to develop polylactide-coglycolide nanoparticles functionalized with polyethylene glycol as the drug vehicle for encapsulating quercetin, and further investigated their anticancer potential against the human tongue squamous cell carcinoma cell line HNO-97 by comparing their effica-cy with that of free quercetin and doxorubicin as standard chemotherapeutic control. Quercetin NPs (QNPs) were synthesized and characterized for particle size, zeta potential, and entrapment efficiency via dynamic light scattering and for morphology via transmission electron microsco-py. The cytotoxicity was evaluated at two time intervals (4 and 24 hours) via the MTT assay. Apoptosis analysis was performed via flow cytometry, and the gene expression levels of Bax, Bcl-2, and PI3K were evaluated via RT-qPCR. After 24 hours of treatment, the in vitro cell cyto-toxicity study revealed that, compared with free quercetin (59.7 µM) and DOX (74.7 µM), QNPs exhibited superior cytotoxicity (IC₅₀ = 41.4 µM). The anticancer efficacy of the QNPs was fur-ther confirmed by enhanced cellular apoptosis. Moreover, treating cells with QNPs resulted in increase in the Bax expression level and the decrease in the Bcl-2 and PI3K expression levels, resulting in the highest Bax/Bcl-2 ratio (31.03). In conclusion, the overall study results suggest that quercetin encapsulated PLGA-PEG nanoparticles may serve as potential drug candidates for the treatment of human tongue squamous cell carcinoma.
- Open Access
- 18 September 2023
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 35 (1) , 1-6
Mandibular small cell osteosarcoma: a case report and review of literature
Background: Small cell osteosarcoma is an extremely rare histopathological variant of conventional osteosarcoma. Due to nonspecific symptoms, most osteosarcomas of the jaws are misdiagnosed as periapical abscesses and mistreated by teeth extraction and drainage. Case presentation: We report, to our knowledge, the seventh case of small cell osteosarcoma in gnathic sites affecting the mandible of an old female with history of a large painful swelling related to the right mandibular molar area for 2 months. Cone-beam computed tomography scan showed an osteolytic lesion related to the lower molar area with involvement of the inferior alveolar nerve. An incisional biopsy was taken, and after histopathological examination and immunohistochemical staining, a diagnosis of small cell osteosarcoma was reached. Hemi-mandibulectomy was performed by a maxillofacial surgeon. No clinical evidence for recurrence was noted until manuscript writing. Conclusion: Accurate diagnosis is very important, and general practitioners should be aware of this entity considering that small cell osteosarcoma has a poor prognosis when compared to conventional osteosarcoma.
- 18 September 2023
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 35 (1) , 1-6
Open AccessMandibular small cell osteosarcoma: a case report and review of literature
Background: Small cell osteosarcoma is an extremely rare histopathological variant of conventional osteosarcoma. Due to nonspecific symptoms, most osteosarcomas of the jaws are misdiagnosed as periapical abscesses and mistreated by teeth extraction and drainage. Case presentation: We report, to our knowledge, the seventh case of small cell osteosarcoma in gnathic sites affecting the mandible of an old female with history of a large painful swelling related to the right mandibular molar area for 2 months. Cone-beam computed tomography scan showed an osteolytic lesion related to the lower molar area with involvement of the inferior alveolar nerve. An incisional biopsy was taken, and after histopathological examination and immunohistochemical staining, a diagnosis of small cell osteosarcoma was reached. Hemi-mandibulectomy was performed by a maxillofacial surgeon. No clinical evidence for recurrence was noted until manuscript writing. Conclusion: Accurate diagnosis is very important, and general practitioners should be aware of this entity considering that small cell osteosarcoma has a poor prognosis when compared to conventional osteosarcoma.
- Open Access
- 25 November 2020
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-8
Toluidine blue versus frozen section for assessment of mucosal tumor margins in oral squamous cell carcinoma
Background: When the resected specimen is sent for intraoperative margin assessment, all margins are grossly checked, and selected margins undergo a frozen section (FS) examination. Therefore, there is a possibility of sampling error. This study evaluated the effectiveness of using toluidine blue (TB) as an intraoperative triage screening tool to detect positive mucosal margins of the resected specimens of oral squamous cell carcinoma (OSCC) and serve as a guide for FS sampling. Methods: Surgical samples of 30 consecutive patients with biopsy-proven OSCC were included in the study. A total of 140 mucosal margins were analyzed intraoperatively by TB and FS, the results were compared with the final histopathology. Results: Of the 140 examined mucosal tumor margins, 14 stained positives with TB, six were true-positives, eight were false-positives, and there were no false-negatives, as confirmed by final histopathology of the same margins. The diagnostic performance measures were sensitivity 100.0%; specificity 94.0%; positive predictive value (PPV) 42.9%; negative predictive value (NPV) 100.0%; and accuracy 94.3% (95% CI: 89.0–97.5%). For FS, there were three true-positives, three false-negatives, and no false-positives. The diagnostic performance measures were sensitivity 50.0%; specificity 100.0%; PPV 100.0%; NPV 97.8%; and accuracy 97.9% (95% CI: 93.9–99.6%). Conclusion: TB is less specific but more sensitive than FS for detecting positive mucosal margins of resected OSCC. Screening the tumor mucosal margins with TB before FS sampling may help identify more tumor-bearing margins. Trial registration: This trial was registered at ClinicalTrials.gov. Registration number: NCT03554967. Registration date: June 13, 2018.
- 25 November 2020
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-8
Open AccessToluidine blue versus frozen section for assessment of mucosal tumor margins in oral squamous cell carcinoma
Background: When the resected specimen is sent for intraoperative margin assessment, all margins are grossly checked, and selected margins undergo a frozen section (FS) examination. Therefore, there is a possibility of sampling error. This study evaluated the effectiveness of using toluidine blue (TB) as an intraoperative triage screening tool to detect positive mucosal margins of the resected specimens of oral squamous cell carcinoma (OSCC) and serve as a guide for FS sampling. Methods: Surgical samples of 30 consecutive patients with biopsy-proven OSCC were included in the study. A total of 140 mucosal margins were analyzed intraoperatively by TB and FS, the results were compared with the final histopathology. Results: Of the 140 examined mucosal tumor margins, 14 stained positives with TB, six were true-positives, eight were false-positives, and there were no false-negatives, as confirmed by final histopathology of the same margins. The diagnostic performance measures were sensitivity 100.0%; specificity 94.0%; positive predictive value (PPV) 42.9%; negative predictive value (NPV) 100.0%; and accuracy 94.3% (95% CI: 89.0–97.5%). For FS, there were three true-positives, three false-negatives, and no false-positives. The diagnostic performance measures were sensitivity 50.0%; specificity 100.0%; PPV 100.0%; NPV 97.8%; and accuracy 97.9% (95% CI: 93.9–99.6%). Conclusion: TB is less specific but more sensitive than FS for detecting positive mucosal margins of resected OSCC. Screening the tumor mucosal margins with TB before FS sampling may help identify more tumor-bearing margins. Trial registration: This trial was registered at ClinicalTrials.gov. Registration number: NCT03554967. Registration date: June 13, 2018.